Fortis Healthcare Ltd.

The company earns most of its money from patient billing across its hospital network, split among self-paying patients, government health schemes, corporate accounts, third-party administrators and international patients, with a smaller stream from standalone diagnostic testing. Revenue and profit have grown together over multiple recent years, with net income staying positive throughout that stretch.

This is CompanyGraph's interpretation of the mechanism, not something independently verified: growth here looks like adding physical treatment capacity, new beds, leased or newly opened hospitals and acquired facilities, because a single site's output is capped by how many beds it operates and how full they run. A large share of the balance sheet sits in long-lived physical assets that have not yet been heavily depreciated, consistent with a system still in the middle of building out capacity rather than one running a mature, largely depreciated estate. Its own materials describe at least one of its hospitals running close to its ceiling, with new capacity being brought on rather than more volume being pushed through the same beds. A very large number of other companies CompanyGraph tracks are built the same way, growing by adding more of the same capped physical unit rather than by scaling one unit indefinitely.

The company sits downstream of a range of other industries that supply it, and its own materials describe its sourcing as overwhelmingly domestic and substantially from small or medium producers, though the specific goods are not identified. It also depends on skilled clinical staff to deliver care and, for some capital equipment, on vendors it pays in foreign currency.

A number of downstream industries rely on services this company supplies. Directly, its patients and payors span people paying for their own care, patients travelling from abroad, government and public-sector health schemes, private corporate arrangements, and organizations that administer claims on patients' behalf.

The evidence here supports describing where this company sits rather than whether rivals could replicate it. It runs the same broad kind of capacity-capped conversion system as a very large number of other companies across many different industries, so that underlying shape is common rather than distinctive to it. Its own materials point to clinical governance, standardized protocols, specialist staffing and outside clinical accreditation as what it presents as its own basis for competing, but nothing available here lets CompanyGraph judge whether competitors could reproduce that.

The company's own account names physical bed capacity as a binding limit at one of its hospitals, describing occupancy there as close to full and, in its own words, 'almost unmanageable,' with new beds being brought on specifically to relieve that ceiling. This matches a broader pattern CompanyGraph tests for this kind of business, that a fixed physical plant caps how much it can convert into output at any one time, though the evidence here speaks to one named site rather than to the system as a whole.

The company's own account discloses a currency exposure: it receives some payments in foreign currency from patients travelling from abroad while paying some overseas vendors in foreign currency for capital equipment, and it describes these two flows as only a partial natural hedge against each other rather than a full offset. This is the one company-specific exposure named in what is available here; nothing on file describes customer concentration or single-source input dependencies for this company specifically.

Its own materials name securities-market and corporate-law regulation as governing its listed structure, and its hospitals operate under accreditation from outside clinical-quality bodies that assess and certify them. It also discloses a currency exposure, since it receives some payments from patients travelling from abroad and pays some overseas vendors in foreign currency for capital equipment, which it describes as only a partial natural offset rather than a full hedge. Beyond these, businesses built around fixed physical treatment capacity generally face pressure to keep that capacity filled and running near its limits, though whether that pressure is currently intense for this company specifically is not something the evidence here measures.